Back to search

Article

Ceritinib for ALK-Rearranged Non–Small-Cell Lung Cancer

2014-04-01

Abstract excerpt

Crizotinib-resistance in ALK -translocation–positive non–small-cell Lung Cancer (NSCLC) is a major problem that often occurs within 1 year of treatment. One-third of patients are known to develop resistance via acquired mutations in the ALK tyrosine kinase domain or ALK gene amplification. Ceritinib is a second-generation oral tyrosine kinase inhibitor of ALK. Ceritinib does not target the MET prototype oncogene b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f90f1976-dc71-5c37-832a-6a2c12d5474c
DOI
10.1056/nejm-jw.na34146
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ceritinib for ALK-Rearranged Non–Small-Cell Lung CancerDOI 10.1056/nejm-jw.na34146
Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Semantic proximity
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity
Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity
Second-generation ALK inhibitors: filling the non "MET" gap.Semantic proximity
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.Semantic proximity
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.Semantic proximity
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.Semantic proximity
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Semantic proximity
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.Semantic proximity
A Clinical Research of Ceritinib Treating Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer With Brain MetastasisSemantic proximity
Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistanceSemantic proximity
Select a neighboring publication to make it the new centre.